keyword
MENU ▼
Read by QxMD icon Read
search

managment tnbc

keyword
https://www.readbyqxmd.com/read/29310608/epoxyazadiradione-suppresses-breast-tumor-growth-through-mitochondrial-depolarization-and-caspase-dependent-apoptosis-by-targeting-pi3k-akt-pathway
#1
Dhiraj Kumar, Saikat Haldar, Mahadeo Gorain, Santosh Kumar, Fayaj A Mulani, Amit S Yadav, Lucio Miele, Hirekodathakallu V Thulasiram, Gopal C Kundu
BACKGROUND: Breast cancer is one of the most commonly diagnosed invasive cancers among women around the world. Among several subtypes, triple negative breast cancer (TNBC) is highly aggressive and chemoresistant. Treatment of TNBC patients has been challenging due to heterogeneity and devoid of well-defined molecular targets. Thus, identification of novel effective and selective agents against TNBC is essential. METHODS: We used epoxyazadiradione to assess the cell viability, mitochondrial potential, ROS level, cell migration, apoptosis and protein expression in cell culture models of TNBC MDA-MB-231 and ER+ MCF-7 breast cancer cells...
January 8, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29285353/triple-negative-breast-cancer-and-its-association-with-obesity
#2
Heng Sun, Jing Zou, Ling Chen, Xuyu Zu, Gebo Wen, Jing Zhong
Triple-negative breast cancer (TNBC) is a subtype of breast cancer that lacks expression of the estrogen and progesterone receptor and does not overexpress human epidermal growth factor 2 receptor protein. TNBC is associated with special characteristics, including aggressiveness, poor prognosis and poor response to treatment, and has been attracting increasing attention worldwide. Obesity is a well-documented factor exerting a significant effect on the development of breast cancer, including TNBC. The purpose of the present review was to focus on the association between obesity and TNBC and provide a summary of novel research findings...
December 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29249020/multi-omic-approach-decodes-paradoxes-of-the-triple-negative-breast-cancer-lessons-for-predictive-preventive-and-personalised-medicine
#3
Olga Golubnitschaja, Nora Filep, Kristina Yeghiazaryan, Henricus Johannes Blom, Martin Hofmann-Apitius, Walther Kuhn
Breast cancer epidemic in the early twenty-first century results in around two million new cases and half-a-million of the disease-related deaths registered annually worldwide. A particularly dramatic situation is attributed to some specific patient subgroups such as the triple-negative breast cancer (TNBC). TNBC is a particularly aggressive type of breast cancer lacking clear diagnostic approach and targeted therapies. Consequently, more than 50% of the TNBC patients die of the metastatic BC within the first 6 months of the diagnosis...
December 16, 2017: Amino Acids
https://www.readbyqxmd.com/read/29235566/long-term-survival-outcomes-of-triple-receptor-negative-breast-cancer-survivors-who-are-disease-free-at-5-years-and-relationship-with-low-hormone-receptor-positivity
#4
S M Reddy, C H Barcenas, A K Sinha, L Hsu, S L Moulder, D Tripathy, G N Hortobagyi, V Valero
BACKGROUND: We counsel our triple-negative breast cancer (TNBC) patients that the risk of recurrence is highest in the first 5 years after diagnosis. However, there are limited data with extended follow-up on the frequency, characteristics, and predictors of late events. METHODS: We queried the MD Anderson Breast Cancer Management System database to identify patients with stage I-III TNBC who were disease free at 5 years from diagnosis. The Kaplan-Meier method was used to estimate yearly recurrence-free interval (RFI), recurrence-free survival (RFS), and distant relapse-free survival (DRFS), as defined by the STEEP criteria...
December 12, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/29191181/immunohistochemistry-defined-subtypes-of-breast-cancer-in-678-sudanese-and-eritrean-women-hospitals-based-case-series
#5
Asmerom Tesfamariam Sengal, Nada Suliman Haj-Mukhtar, Ahmed Mohammed Elhaj, Shahinaz Bedri, Eva Johanna Kantelhardt, Ahmed A Mohamedani
BACKGROUND: Breast cancer is the most common malignancy accounting for 25% of all cancers in females. In Africa, breast cancer prevalence and mortality are steadily increasing. Knowledge of hormone receptors and human epidermal growth factor receptor-2 (HER-2) expressions are vital for breast cancer management plans and decision making. There is wide regional variation in the proportion of these biomarkers, especially in African countries. Hormone receptors positivity in indigenous African and African American women is considered to be low and triple negative breast cancer is a dominant phenotype...
December 1, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29138528/the-predictive-value-of-pitx2-dna-methylation-for-high-risk-breast-cancer-therapy-current-guidelines-medical-needs-and-challenges
#6
REVIEW
Michaela Aubele, Manfred Schmitt, Rudolf Napieralski, Stefan Paepke, Johannes Ettl, Magdalena Absmaier, Viktor Magdolen, John Martens, John A Foekens, Olaf G Wilhelm, Marion Kiechle
High-risk breast cancer comprises distinct tumor entities such as triple-negative breast cancer (TNBC) which is characterized by lack of estrogen (ER) and progesterone (PR) and the HER2 receptor and breast malignancies which have spread to more than three lymph nodes. For such patients, current (inter)national guidelines recommend anthracycline-based chemotherapy as the standard of care, but not all patients do equally benefit from such a chemotherapy. To further improve therapy decision-making, predictive biomarkers are of high, so far unmet, medical need...
2017: Disease Markers
https://www.readbyqxmd.com/read/29082597/magnetic-resonance-molecular-imaging-of-metastatic-breast-cancer-by-targeting-extradomain-b-fibronectin-in-the-tumor-microenvironment
#7
Zheng Han, Han Cheng, Jenny G Parvani, Zhuxian Zhou, Zheng-Rong Lu
PURPOSE: Non-invasive early accurate detection of malignant breast cancer is paramount to the clinical management of the life-threatening disease. Here, we aim to test a small peptide targeted MRI contrast agent, ZD2-Gd(HP-DO3A), specific to an oncoprotein, extradomain-B fibronectin (EDB-FN), in the tumor microenvironment for MR molecular imaging of breast cancer. METHOD: EDB-FN expression in 4T1 and MDA-MB-231 cancers was analyzed with quantitative real-time PCR and western blot...
October 29, 2017: Magnetic Resonance in Medicine: Official Journal of the Society of Magnetic Resonance in Medicine
https://www.readbyqxmd.com/read/28923217/current-challenges-in-the-management-of-breast-cancer-brain-metastases
#8
REVIEW
Ciara C O'Sullivan, Nicole N Davarpanah, Jame Abraham, Susan E Bates
Approximately 50% of patients with advanced human epidermal growth factor 2 (HER2)-positive breast cancer and triple-negative breast cancer (TNBC) ultimately develop breast cancer brain metastases (BCBM), which are associated with significant morbidity and mortality. The advent of HER2-directed therapy resulted in greatly improved survival outcomes, but unfortunately at the price of an increased cumulative incidence of BCBM. We review challenges in the management of BCBM, and potential treatment strategies, including novel agents such as poly-adenosine diphosphate (ADP) ribose polymerase (PARP) inhibitors (olaparib, veliparib), cyclin-dependent kinase 4/6 (CDK4/6) inhibitors (palbociclib, abemaciclib), and taxane derivatives (eg, ANG1005 and TPI-287)...
April 2017: Seminars in Oncology
https://www.readbyqxmd.com/read/28801472/breast-cancer-immunotherapy-facts-and-hopes
#9
Leisha A Emens
Immunotherapy is revolutionizing the management of multiple solid tumors, and early data have revealed the clinical activity of PD-1/PD-L1 antagonists in small numbers of metastatic breast cancer patients. Clinical activity appears more likely if the tumor is triple negative, PD-L1+, and/or harbors higher levels of TILs. Responses to atezolizumab and pembrolizumab appear to be durable in metastatic triple negative breast cancer (TNBC), suggesting these agents may transform the lives of responding patients. Current clinical efforts are focused on developing immunotherapy combinations that convert non-responders to responders, deepen those responses that do occur, and surmount acquired resistance to immunotherapy...
August 11, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28707744/the-impact-of-molecular-subtype-on-breast-cancer-recurrence-in-young-women-treated-with-contemporary-adjuvant-therapy
#10
Hanan Alabdulkareem, Tiffany Pinchinat, Sarah Khan, Alyssa Landers, Paul Christos, Rache Simmons, Tracy-Ann Moo
Breast cancer is the leading cause of cancer death in women younger than 40 years. Triple-negative breast cancer (TNBC) and human epidermal growth factor receptor-2 (HER2) positive subtypes have a particularly poor prognosis in this age group. The purpose of this study was to compare rates of recurrence among breast cancer subtypes in young patients treated with modern adjuvant systemic therapy. A retrospective review of breast cancer patients managed at a major academic breast center between May 2000 and November 2014 was performed...
July 14, 2017: Breast Journal
https://www.readbyqxmd.com/read/28657689/neoadjuvant-chemotherapy-with-mri-monitoring-for-breast-cancer
#11
R V Dave, R Millican-Slater, D Dodwell, K Horgan, N Sharma
BACKGROUND: Neoadjuvant chemotherapy (NACT) is increasingly being offered to patients with breast cancer. No survival benefit has been demonstrated for NACT, but it may serve to reduce tumour size and improve prognosis through the attainment of a pathological complete response (pCR). The role and mode of MRI monitoring during NACT remain unclear. METHODS: Patients managed with NACT at a UK centre over 7 years were studied using a prospectively maintained database, which also included details of MRI...
August 2017: British Journal of Surgery
https://www.readbyqxmd.com/read/28544579/frizzled7-antibody-functionalized-nanoshells-enable-multivalent-binding-for-wnt-signaling-inhibition-in-triple-negative-breast-cancer-cells
#12
Rachel S Riley, Emily S Day
Antibodies that antagonize cell signaling pathways specific to their targeted receptor are invaluable tools to study and treat malignancies, but their utility is limited by high production costs and treatment dosages. Researchers have shown that antibodies conjugated to nanoparticles display increased affinity for their target relative to freely delivered antibodies due to multivalency, and this study investigates how this multivalency can enable antibody-nanoparticle conjugates to inhibit oncogenic cell signaling more effectively than freely delivered antibodies...
July 2017: Small
https://www.readbyqxmd.com/read/28461119/taraxacum-mongolicum-extract-induced-endoplasmic-reticulum-stress-associated-apoptosis-in-triple-negative-breast-cancer-cells
#13
Xiao-Hong Li, Xi-Ran He, Yan-Yan Zhou, Hai-Yu Zhao, Wen-Xian Zheng, Shan-Tong Jiang, Qun Zhou, Ping-Ping Li, Shu-Yan Han
BACKGROUND: Triple-negative breast cancer (TNBC) is an aggressive and deadly breast cancer subtype with limited treatment options. It is necessary to seek complementary strategies for TNBC management. Taraxacum mongolicum, commonly named as dandelion, is a herb medicine with anti-cancer activity and has been utilized to treat mammary abscess, hyperplasia of mammary glands from ancient time in China, but the scientific evidence and action mechanisms still need to be studied. AIM OF THE STUDY: This study was intended to investigate the therapeutic effect and molecular mechanisms of dandelion extract in TNBC cell line...
July 12, 2017: Journal of Ethnopharmacology
https://www.readbyqxmd.com/read/28410132/tackling-intra-and-inter-tumor-heterogeneity-to-combat-triple-negative-breast-cancer
#14
REVIEW
Nikita Wright, Padmashree C G Rida, Ritu Aneja
Rampant inter-patient and intra-tumor heterogeneity present formidable challenges in the clinical management of triple-negative breast cancer (TNBC) and mandate a "divide-and-conquer" approach wherein deep biomarker profiling drives patient segmentation and development of customized treatments. Genomic and proteomic studies have uncovered several TNBC subtypes each of which represents a distinct disease pathobiology and harbors unique actionable targets that may illuminate sensitivities to specific classes of therapeutics...
June 1, 2017: Frontiers in Bioscience (Landmark Edition)
https://www.readbyqxmd.com/read/28405497/results-of-a-phase-i-ii-study-of-adjuvant-concurrent-carboplatin-and-accelerated-radiotherapy-for-triple-negative-breast-cancer
#15
Silvia C Formenti, Encouse B Golden, Judith D Goldberg, Xiaochun Li, Jessica Taff, Maria B Fenton-Kerimian, Sharanya Chandrasekhar, Sandra Demaria, Yelena Novik
Purpose: To determine feasibility and explore the clinical efficacy of concurrent radiotherapy and carboplatin as adjuvant treatment of triple negative breast cancer (TNBC). Patients and Methods: Women with Stage I-II TNBC were treated after surgery in a phase I-II prospective trial [NCT01289353]. Weekly carboplatin (AUC = 2.0) was delivered for 6 weeks. Concurrent radiotherapy was delivered in the prone position during weeks 2-4, for a total dose of 40.5 Gy in 15 fractions to the breast, and 46.5 Gy in 17 fractions to the tumor bed...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/28382102/bilateral-triple-negative-invasive-breast-cancer-with-a-brca2-mutation-and-glioblastoma-a-case-report-and-literature-review
#16
Ali Raufi, Mohamed Alsharedi, Yousef Khelfa, Maria Tirona
Breast cancer is the second leading cause of death among women in North America. Glioblastoma is the most common primary malignant central nervous system tumor in adults. The majority of hereditary breast cancers are associated with deleterious mutations in the BRCA1 and BRCA2 genes. Although few case reports have described the incidence of glioblastoma in patients previously diagnosed with breast cancer, any association between BRCA2 mutations and glioblastoma has not been demonstrated to date. Herein, we report a woman who is a carrier of a familial BRCA2 mutation, and was previously diagnosed with triple-negative breast cancer (TNBC) and subsequently with a second primary TNBC and glioblastoma...
March 2017: Journal of Breast Cancer
https://www.readbyqxmd.com/read/28277293/prospective-comparison-of-outcome-after-treatment-for-triple-negative-and-non-triple-negative-breast-cancer
#17
D P Joyce, D Murphy, A J Lowery, C Curran, K Barry, C Malone, R McLaughlin, M J Kerin
INTRODUCTION: Triple-negative breast cancers (TNBC) are associated with a poor prognosis owing to an aggressive phenotype. We aimed to carry out a prospective study comparing management strategies and response to therapy in TNBC and non-TNBC patients. METHODS: Data were obtained from a prospectively maintained database of patients treated for breast cancer. RESULTS: A total of 142 TNBC and 142 age-, stage- and NPI-matched non-TNBC patients were treated...
October 27, 2016: Surgeon: Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
https://www.readbyqxmd.com/read/28211614/opportunities-for-improving-triple-negative-breast-cancer-outcomes-results-of-a-population-based-study
#18
COMPARATIVE STUDY
Elisabetta Rapiti, Kim Pinaud, Pierre O Chappuis, Valeria Viassolo, Aurélie Ayme, Isabelle Neyroud-Caspar, Massimo Usel, Christine Bouchardy
Triple-negative breast cancer (TNBC) is associated with a poor prognosis. Surgery, radiotherapy, chemotherapy, and referral for genetic counseling are the standard of care. We assessed TNBC prevalence, management, and outcome using data from the population-based Geneva cancer registry. 2591 women had a first invasive stage I-III breast cancer diagnosed between 2003 and 2011. We compared TNBC to other breast cancers (OBC) by χ(2) -test and logistic regression. Kaplan-Meier survival curves, up to 31-12-2014, were compared using log-rank test...
March 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28194329/understanding-breast-cancer-the-long-and-winding-road
#19
REVIEW
Kiven Erique Lukong
BACKGROUND: Despite a remarkable increase in the depth of our understanding and management of breast cancer in the past 50 years, the disease is still a major public health problem worldwide and poses significant challenges. The palpability of breast tumors has facilitated diagnosis and documentation since ancient times. The earliest descriptions of breast cancer date back to around 3500 BCE. For centuries to follow, theories by Hippocrates (460 BCE) and Galen (200 CE), attributing the cause of breast cancer to an "excess of black bile" and treatment options including the use of opium and castor oil, prevailed...
June 2017: BBA Clinical
https://www.readbyqxmd.com/read/28135048/identification-of-recurrent-brca1-mutation-and-its-clinical-relevance-in-chinese-triple-negative-breast-cancer-cohort
#20
Xiaoran Liu, Huiping Li, Bin Shao, Jianmin Wu, Weiyao Kong, Guohong Song, Hanfang Jiang, Jing Wang, Fengling Wan
Triple-negative breast cancer (TNBC) accounts for 15-20% of all newly diagnosed breast cancers, and is enriched for germline mutation of BRCA. In Asian patients diagnosed with breast cancer, 268 deleterious mutations of BRCA1 and 242 of BRCA2 have been identified so far, including a reported BRCA1 frameshift mutation (rs80350973), apparently found only in Asian people, with a low prevalence of 0.3-1.7% in different breast cancer cohorts. Here, we reported the high prevalence (7.2%) of rs80350973 among 125 Chinese patients with TNBC, which implies its mutational predilection for certain breast cancer subtypes...
March 2017: Cancer Medicine
keyword
keyword
55830
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"